Dr. Shoushtari on the Data from the First-in-Human Trial for Tebentafusp in Advanced Melanoma
November 22nd 2019Alexander N. Shoushtari, MD, discusses the significance of the findings from the first-in-human trial evaluating tebentafusp, a TCR–CD3 bispecific, in patients with advanced melanoma.
Read More